Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration

scientific article published on 01 June 2005

Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/EJI.200526124
P698PubMed publication ID15909311

P50authorThomas M KündigQ105045997
P2093author name stringKent A Smith
Adrian Bot
Pål Johansen
Tazio Storni
Barbara R von Beust
P2860cites workMD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4Q22009943
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 GeneQ22299417
A Toll-like receptor recognizes bacterial DNAQ24290668
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gammaQ24568172
CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines.Q33647526
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in miceQ34006411
Toll meets bacterial CpG-DNA.Q34260232
CpG motifs in bacterial DNA trigger direct B-cell activationQ34307394
CpG motifs in bacterial DNA and their immune effectsQ34542287
Immunotherapeutic uses of CpG oligodeoxynucleotidesQ35730784
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administrationQ38345478
Lymphokine production by human T cells in disease statesQ40661109
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particlesQ40745968
CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responsesQ40776605
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligoQ41007804
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effectsQ45698211
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?Q53284971
CpG-DNA upregulates the major acute-phase proteins SAA and SAP.Q54021251
H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategiesQ73129213
Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteinsQ73420690
CpG DNA induces stronger immune responses with less toxicity than other adjuvantsQ73502903
CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvantsQ73814892
CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responsesQ74027097
P433issue6
P304page(s)1869-1876
P577publication date2005-06-01
P1433published inEuropean Journal of ImmunologyQ5412727
P1476titleImproving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration
P478volume35

Reverse relations

cites work (P2860)
Q43601291A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors
Q36496104A review of CpGs and their relevance to aquaculture
Q38912244Allergen immunotherapy: routes, safety, efficacy, and mode of action
Q27687250Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases
Q83575548Antitumor activity mediated by CpG: the route of administration is critical
Q89944637Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route
Q47841051Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides
Q35229225In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles
Q36970017Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial
Q35155423Intralymphatic immunotherapy
Q35389863Intralymphatic immunotherapy and vaccination in mice
Q35224136Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration
Q37374278Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.
Q99711516Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis
Q93116271NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices
Q88143332Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma
Q92343873Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases
Q37700490Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice
Q41526077Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity
Q33519555Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice
Q27335400Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice
Q80625739Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do